Relacorilant and Budesonide Oral Inhalation: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Relacorilant
Budesonide Oral Inhalation
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced relacorilant exposure and reduced efficacy of relacorilant, altered (reduced/increased) glucocorticoids exposure, reduced efficacy of glucocorticoids and an increased risk of glucocorticoids
Interaction Deep Dive
Avoid coadministration of relacorilant and glucocorticoids that are also CYP3A4 substrates, unless otherwise recommended as it may reduce the exposure of relacorilant and/or glucocorticoids resulting in reduced efficacy of exposure and may also increase exposures of glucocorticoids that are also CYP3A4 substrates. If coadministration cannot be avoided, monitor patients for reduced effectiveness of relacorilant and glucocorticoids. Concomitant use of relacorilant and glucocorticoids is contraindicated for the use in patients with immunosuppression in organ transplantation1.
Why it happens (mechanism)
Pharmacologic antagonism; inhibition of CYP3A4-substrate metabolism by relacorilant
Literature reports
1 report — tap to read
a) In drug interaction studies, coadministration of relacorilant, 350 mg under fasted condition (1.8 times the relacorilant exposure at the recommended dosage) once daily for 10 days with midazolam (CYP3A4 substrate) increased Cmax by 3.1-fold and AUC by 8.9-fold 1.
Common questions
Can I take Relacorilant and Budesonide Oral Inhalation together?
Reduced relacorilant exposure and reduced efficacy of relacorilant, altered (reduced/increased) glucocorticoids exposure, reduced efficacy of glucocorticoids and an increased risk of glucocorticoids Always confirm with your pharmacist or prescriber before making any change.
How serious is the Relacorilant and Budesonide Oral Inhalation interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Relacorilant or Budesonide Oral Inhalation need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: LIFYORLI™ oral capsules, relacorilant oral capsules. Corcept Therapeutics Incorporated (Per Manufacturer), Redwood City, CA, 2026. DailyMed
Keep reading about Relacorilant
Keep reading about Budesonide Oral Inhalation
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist